← All diseases Cancer

Liver cancer

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most robust evidence (78)Meta-analysis (34)Treatment guideline (5)Systematic review (18)Randomized trial (14)Phase 3 study (7)Clinical trial (608)Review article (448)Early study (phase 1 or 2) (26)Laboratory or animal research (164)Case report (110)Commentary or editorial (69)Retracted publication (8)Concerns have been raised (1) Studies currently recruiting participants only (41)

Filter

Publications and studies (3377)

• A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116. (2023/11/13) ♡
• Development of a Liver Disease-Specific Large Language Model Chat Interface using Retrieval Augmented Generation. (2023/11/10) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Loss of Krüppel-like factor-10 facilitates the development of chemical-induced liver cancer in mice. (2023/11/09) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Utility of ultrasonography in a mouse model of non-alcoholic steatohepatitis induced by a choline-deficient, high-fat diet and dextran sulfate sodium. (2023/11/08) ♡
• Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis. (2023/11/07) ♡
• DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma. (2023/11/03) ♡
• Aconite aqueous extract inhibits the growth of hepatocellular carcinoma through CCL2-dependent enhancement of natural killer cell infiltration. (2023/11/01) ♡
• Mechanistic engineering of celastrol liposomes induces ferroptosis and apoptosis by directly targeting VDAC2 in hepatocellular carcinoma. (2023/11/01) ♡
• Treatment guidelineiAn official agreement between doctors about how this disease should be treated. This is not a single study but the conclusion of an entire medical field. EASL-ERN position paper on liver involvement in patients with Fontan-type circulation. (2023/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatocellular carcinoma and sarcopenia: a narrative review. (2023/11/01) ♡
• Racial Disparities in Candidates for Hepatocellular Carcinoma Liver Transplant After 6-Month Wait Policy Change. (2023/11/01) ♡
• [LIVER TRANSPLANT CHALLENGES 2023]. (2023/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Von Willebrand Factor as a Biomarker for Liver Disease - An Update. (2023/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Deciphering the tumour immune microenvironment of hepatocellular carcinoma. (2023/11/01) ♡
• Diet-induced rewiring of the Wnt gene regulatory network connects aberrant splicing to fatty liver and liver cancer in DIAMOND mice. (2023/10/31) ♡
• Impact of Liver Fibrosis Severity on Oncological Prognosis in Hepatocellular Carcinoma. (2023/10/31) ♡
• Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection Exhibited Favorable Survival from Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. (2023/10/30) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Construction of web-based prediction nomogram models for cancer-specific survival in patients at stage IV of hepatocellular carcinoma depending on SEER database. (2023/10/28) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study. (2023/10/27) ♡
• CT Radiomics Features of Abdominal Adipose and Muscle Tissues Can Predict the Postoperative Early Recurrence of Hepatocellular Carcinoma. (2023/10/27) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Emerging theragnostic radionuclide applications for hepatocellular carcinoma. (2023/10/25) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Cost effectiveness of immune checkpoint inhibitors for treatment of Hepatocellular Carcinoma: A systematic review and meta-analysis. (2023/10/24) ♡
• Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation. (2023/10/23) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Expert management of congenital portosystemic shunts and their complications. (2023/10/20) ♡
• Unlocking Colchicine's Untapped Potential: A Paradigm Shift in Hepatocellular Carcinoma Prevention. (2023/10/18) ♡
• Diabetes and the risk of cirrhosis and HCC: An analysis of the UK Biobank. (2023/10/18) ♡
• Gut insulin action protects from hepatocarcinogenesis in diabetic mice comorbid with nonalcoholic steatohepatitis. (2023/10/18) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Management of Nonmalignant Portal Vein Thrombosis in Cirrhosis. (2023/10/18) ♡
• Genipin-activating PPARγ impedes CCR2-mediated macrophage infiltration into postoperative liver to suppress recurrence of hepatocellular carcinoma. (2023/10/16) ♡
• Phospholipid isotope tracing reveals β-catenin-driven suppression of phosphatidylcholine metabolism in hepatocellular carcinoma. (2023/10/16) ♡
• Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis. (2023/10/14) ♡
• The proteasome activator subunit PSME1 promotes HBV replication by inhibiting the degradation of HBV core protein. (2023/10/14) ♡
• Amphiregulin Induces iNOS and COX-2 Expression through NF-κB and MAPK Signaling in Hepatic Inflammation. (2023/10/11) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Anisomeles indica Extracts and Their Constituents Suppress the Protein Expression of ACE2 and TMPRSS2 In Vivo and In Vitro. (2023/10/11) ♡
• Real-World Data on the Diagnosis, Treatment, and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT Study. (2023/10/09) ♡
• Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with WNT/β-Catenin Mutations. (2023/10/09) ♡
• Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma. (2023/10/06) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Prevalence of Hepatocellular Carcinoma in Hepatitis B Population within Southeast Asia: A Systematic Review and Meta-Analysis of 39,050 Participants. (2023/10/06) ♡
• Cytostatic and cytotoxic effects of a hot water and methanol extract of Acokanthera oppositifolia in HepG2 hepatocarcinoma cells (2023/10/05) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Medicinal plant molecules against hepatitis C virus: Current status and future prospect. (2023/10/01) ♡
• Coptidis rhizoma and evodiae fructus against lipid droplet deposition in nonalcoholic fatty liver disease-related liver cancer by AKT. (2023/10/01) ♡
• Chemical profiling and investigation of molecular mechanisms underlying anti-hepatocellular carcinoma activity of extracts from Polygonum perfoliatum L. (2023/10/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Advancing prognostic precision in hepatocellular carcinoma: a paradigm shift towards machine learning. (2023/10/01) ♡
• Malignant Portal Vein Thrombosis with No Obvious Liver Parenchymal Mass on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. (2023/10/01) ♡
• Cavernous Hepatic Hemangioma at 18F-Choline Positron Emission Tomography-Computed Tomography: Be Aware of the Pitfall. (2023/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. A Review Of Mri Appearances Of Lipiodol In Conventional Tace (Ctace) Treated Hepatocellular Carcinomas. (2023/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Translational Relevance of Rodent Models to Predict Human Liver Disease. (2023/10/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Melatonin Mitigates the Progression of Chemically Induced Hepatocellular Carcinoma in Rats via Targeting Wnt/β-Catenin Pathway, and Small Noncoding Mir-let-7b. (2023/10/01) ♡
• Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma. (2023/10/01) ♡
• PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma. (2023/09/30) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.